This product is used for the treatment of periocular wrinkles and for lip and eyebrow contouring. Injected into the superficial dermis, hypercorrections should be avoided. If necessary, the physician can perform corrections with both the serial puncture and linear retrograde techniques, according to her dexterity. It is recommended that you massage the treated parts.
A NEW GENERATION OF CROSS-LINKED HYALURONIC ACID FILLERS FOR THE TREATMENT OF SKIN BLEMISHES
EVRYÀL Cross-linked is a sterile, highly tolerated, viscoelastic filler made with cross-linked hyaluronic acid, ideal for subcutaneous applications. EVRYÀL Cross-linked helps increase the volume of the epidermal tissue thanks to the natural ability of hydrophilic hyaluronic acid molecules to attract a moderate amount of water molecules and bond with them. This allows the integration of the intercellular matrix, whilst filling intradermal spaces and making the tissues firmer.
The cross-linked hyaluronic acid contained in the product makes this filling effect longer lasting and more stable. In fact, unlike linear hyaluronic acid, the skin slowly absorbs EVRYÀL Cross-linked in 6 to 8 months, looking more natural for longer. In addition to safety, BDDE – the cross-linking agent – provides
effective results, thereby meeting market requirements. EVRYÀL Cross-linked is a CE 0373 injectable, apyrogenic, resorbable medical device made with cross-linked hyaluronic acid created from non-animal sourced bacterial bio-fermentation. It is a colourless monophasic gel contained in a disposable pre-filled, ergonomic syringe with a Luer Lock adapter. The syringe is equipped with a plastic support that makes it easy to handle. Its accurate graduation allows you to control and read the volume of injected product. Electronic verifications carried out throughout the entire filler production and packaging process, based on the use of state of the art technology, ensure quality, purity, and safety. These production standards, together with the extremely low concentration of nucleic acids and protein, and the bacterial endoxin rate < 0.5 EU/ml (much lower than the limit established by the European Pharmacopoeia for injectable products) minimise any hypersensitivity reaction.